Mucins are high molecular weight proteins that are highly O-glycosylated. Tumor-produced mucins are detected in tumor tissues and/or the bloodstream of cancer patients, and thus have been used as tumor markers. It has been reported that patients with higher amounts of mucins in their bloodstreams exhibit a lower 5-year survival rate, suggesting that mucins have some biological effect in cancer patients. Since mucins have a variety of sugar chains, it is possible that mucins in the bloodstream interact with some lectins on endothelial cells and/or immune cells. Recent reports suggested that tumor-produced mucins suppress immune function. Here we mainly describe the immunosuppressive effect on B cells through the ligation of mucins with Siglec-2.
A. Introduction
Mucin is a high molecular weight glycoprotein that protects the respiratory and gastrointestinal tracts, and more than 20 mucin genes are known at present (1) . They can be classified as membrane-bound and secreted mucins, including MUC1 and MUC2, respectively. The extracellular regions of some membrane-bound mucins are shed from the cell surface. Mucins generally possess unique tandem repeat domains, which are rich in serine and threonine residues. The number of tandem repeats varies among each MUC species and they are genetically polymorphic. For example, the number of tandem repeats of MUC2 varies from approximately 100 to 115 among individuals. Since tandem repeats are highly O-glycosylated, the molecules comprise over 50% carbohydrate by weight. Mucins are produced by epithelial cells and transported to their apical surface. Upon malignant transformation, mucins are expressed on all aspects of cells because of the loss of polarity, resulting in secretion of the mucins into tumor tissues and/or the bloodstream of cancer patients, and these mucins have a variety of sugar chains including tumor-associated carbohydrate antigens because of the changes in the expression level of glycosyltransferases, and furthermore the expression of the core protein itself also increases. Mucins themselves and/or associated carbohydrate antigens have been used as tumor markers, such as MUC1 (CA15-3), MUC16 (CA125), and sialyl Lewis a (CA19-9). There have been many reports that amounts of mucins in the bloodstreams of cancer patients are related with a 5-year survival rate (2) . Not only the amounts of mucins, but also the structures of carbohydrate chains borne by the core proteins are also correlated with survival rate (3) . Therefore, the mucins in the bloodstream may have some biological function, such as down-immunomodulation.
Since a variety of lectins are expressed on immune cells, we postulated that mucins in the bloodstreams of cancer patients could interact with these lectins, leading to prevention of a normal interaction with endogenous ligands and induction of unusual signal transduction. In fact, some reports demonstrated that Siglecs (sialic acid-binding Ig-like lectins) and galectins interact with mucins (4-6). Here we mainly describe the immunosuppressive effect of mucins through ligation with Siglec-2. B cells express a variety of lectins, one of which is Siglec-2, a member of the Siglec family. Siglec-2 has ITIMs in the cytoplasmic region and negatively regulates B cell receptor (BCR) signaling induced by antigenbinding. Mucins carries various carbohydrate antigens including a sialyl-Tn antigen, which is reported to bind to Siglec-2 (7). These facts allow the supposition that mucins in the bloodstream affect B cells via Siglec-2. Therefore, we examined the effect of mucins on B cell function using LS 180-cell produced mucins.
B. Binding of Mucins to Siglec-2 and Effects on B Cell Signal Transduction
To investigate the binding of tumor-derived mucins to Siglec-2, recombinant soluble human Siglec-2 was prepared and its binding ability was determined using the plate immobilized LS 180-cell-produced mucins. Recombinant Siglec-2 bound to the mucins in a dose-dependent manner, whereas the mucins did not bind to the R120A mutant, which lacks the binding ability as to sialylated ligands. These results indicate that Siglec-2 binds to mucins through its sialic acidbinding site (8) .
Next, we examined the effects of mucins on B cell signal transduction. After antigen ligation, tyrosines within the ITAM of CD79a (Igα) and CD79b (Igβ) that comprise the BCR are phosphorylated by tyrosine kinase Lyn, and then ERK-1/2 are phosphorylated, resulting in B cell activation. Siglec-2 present in the proximity of BCR is also phospholylated by Lyn, to which tyrosine phosphatase SHP-1 is recruited. Thus, signal transduction through the BCR is down-modulated via dephosphorylation, leading to suppression of B cell activation. The effect of Siglec-2 ligation on BCR-mediated signal transduction has been studied by using antibodies toward Siglec-2. It has been reported that ligation of anti-IgM F(ab') 2 to the BCR in the presence of antiSiglec-2 antibodies suppresses the phosphorylation of Siglec-2 and the recruitment of SHP-1, resulting in enhancement of ERK-1/2 phosphorylation (9). Thus, we also considered that the ligation of mucins to Siglec-2 has a similar effect upon BCR-mediated signal transduction. When B cells were stimulated through the BCR in the presence of mucins, the phosphorylation of Siglec-2 and recruitment of SHP-1 were down-modulated by mucins in a dose-dependent manner (Fig.  1A) . These results let us to predict that the ligation of mucins with Siglec-2 would enhance the BCR-mediated signal transduction. Therefore, we next examined phosphorylation of ERK-1/2 after BCR ligation in the presence of mucins. Unexpectedly, the resultant phosphorylation of ERK-1/2 was suppressed by mucins in a dose-dependent manner (Fig. 1B) . This finding suggests that mucins suppress B cell activation and differentiation induced by antigen ligation, which is in contrast with the results of previous studies using anti-Siglec-2 antibodies. Since mucins and anti-Siglec-2 antibodies have multiple and divalent binding sites for Siglec-2, respectively, this different effect on the B cell activation may be due to the different valency. As described above, ligation of antiIgM F(ab') 2 at 37 ̊C for 10 min, and then stimulated with anti-IgM F(ab') 2 at 37 ̊C for 3 min. Siglec-2 and SHP-1 prepared from the cell lysate were subjected to SDS-PAGE and Western blotting, and then phosphorylated tyrosines, SHP-1 and Siglec-2 were detected. The intensities of the bands were determined with Image J software and normalized as to the levels detected in experiments performed in the presence of anti-IgM F(ab') 2 and in the absence of LS 180 mucin (mean ± SD, n=3). (B) Daudi cells were stimulated as described above except that the incubation time was 5 min. The cell lysate was directly subjected to SDS-PAGE, followed by Western blotting, and then phosphorylated ERK-1/2 and ERK-1/2 were detected. The relative amounts of phosphorylated ERK-1/2 were determined and normalized as described above. phosphorylation. This result has been considered that the ligation of antibodies to Siglec-2 sequesters it away from the BCR. On the other hand, because mucins are huge molecules with lengths of ~ 500 nm and possess an extremely large number of binding sites for Siglec-2, it is speculated that mucins may be able to crosslink many Siglec-2 molecules present over a wide area of the cell surface, resulting in a crucial effect on the movement of cell surface molecules including the BCR. Recently, many studies suggested that lipid rafts play an important role in signal transduction. In the case of B cells, it is proposed that crosslinking of the BCR by antigens, which increases its affinity for the lipid rafts, results in the movement of the BCR to the lipid rafts. The BCR is phosphorylated in the lipid rafts by Lyn, which triggers a signal transduction cascade (10) (11) (12) (13) (14) (15) (16) . Ordinarily, Siglec-2 also moves to the lipid rafts and is phosphorylated there, resulting in down-modulation of the B cell activation signal (17, 18) . Taken these findings together with our results, we speculate that the ligation of mucins to Siglec-2 prevents the movement of Siglec-2 and the BCR to lipid rafts (Fig. 2) . Yu et al. reported that a synthetic glycan ligand of Siglec-2 blocks the translocation of Siglec-2 to lipid rafts (19) . However, the synthetic glycan blocked the translocation of Siglec-2 but not that of the BCR. The level of valency or affinity may be relevant to this biological effect.
C. Effects of Mucins on Splenic B Cells in the TumorBearing State
Through in vitro experiments, we have demonstrated that tumor-produced mucins bind to Siglec-2 and that the ligation of Siglec-2 with mucins suppresses BCR-mediated signal transduction. These results suggest that mucins in antigens, which increases its affinity for lipid rafts, leads to the movement of the BCR to lipid rafts. The BCR is phosphorylated in the lipid rafts by Lyn, which triggers a signal transduction cascade. In the absence of mucins, Siglec-2 also moves to the lipid rafts, followed by phosphorylation and recruitment of SHP-1, resulting in down-modulation of the B cell activation signal. In the presence of mucins, the bridging of multiple Siglec-2 molecules by mucins interferes with the movement of membrane proteins including the BCR to lipid rafts, resulting in interruption of ERK-1/2 phosphorylation. (20, 21) , but TA3-St cells, a subline of them, do not (22) . In addition, epiglycanin can be detected in ascites fluid as well as in the bloodstream of TA3-Ha-bearing mice (23) . Epiglycanin has been demonstrated to carry an α2,6 sialylated glycan on lectin blot analyses of ascites fluid of TA3-Ha-bearing mice using SSA, which recognizes α2,6-linked sialic acids. Next, we confirmed the binding ability of recombinant soluble Siglec-2 using an epiglycanin-immobilized plate. Furthermore, when splenic B cells were stimulated with anti-IgM F(ab') 2 , tyrosyl phosphorylation of Siglec-2, recruitment of SHP-1, and phosphorylation of ERK-1/2 decreased in the presence of epiglycanin. These results suggest that down-modulation of B cell signal transduction through ligation of mucins to Siglec-2 occurs in both mouse and human cells (24) . Thus, epiglycanin is revealed to be a potent ligand for Siglec-2 in the TA3-Ha tumor-bearing state.
Since mucins down-modulated the signal transduction through the BCR, it was expected that B cells in secondary lymphoid tissues, where immune responses against antigens occur, could be affected by mucins in the tumor-bearing state. In addition, the spleen is one of the organs which passes a large amount of blood through the splenic artery. In fact, when fluorescein-labeled mucins were injected intravenously, most of the mucins were taken up by the liver, but a small amount of mucins was definitely detected in the spleen. So, we decided to examine the splenic B cells of tumor-bearingmice. Splenocytes were prepared from TA3-Ha-or TA3-Stbearing mice on day 8 after inoculation of tumor cells, and then analyzed with a flow cytometer. Although similar levels of B220-positive cells were present among the splenocytes of TA3-St-bearing mice and control mice, they were significantly reduced among those of TA3-Ha-bearing mice. Murine splenic B cells are mainly classified into three subsets, i. e. newly formed B (NFB) cells, which transit from the bone marrow, follicular B (FOB) cells, which are localized in follicles, and marginal zone B (MZB) cells, which are localized in the marginal zone between the red and white pulp (Fig. 3) . We tried to see whether specific subpopulations were reduced in TA3-Ha-bearing mice. Interestingly, MZB cells (B220 + CD23 low CD21 high ) were significantly reduced only in TA3-Ha-bearing mice (Fig. 4A) . It is well known that splenic MZB cells highly express CD21 and CD1d. The expression of CD21 and CD1d in splenocytes prepared from TA3-Ha-and TA3-St-bearing, and control mice was compared (Fig. 4B) . As expected, the CD21 high CD1d high population was clearly reduced in TA3-Ha -bearing mice, which was consistent with the results shown in Fig. 3A . Next, we also examined the reduction of splenic MZB cells in TA3-Ha-bearing mice immunochemically. Frozen sections of spleens were prepared from TA3-Ha-or TA3-Stbearing mice on day 8 after inoculation of tumor cells, and immunochemical staining was performed using anti-CD1d and anti-Siglec-2 antibodies (Fig. 5) . To confirm the location of the marginal zone, sinus-lining cells, which are localized close to the white pulp on the inner side of the marginal zone (25) , were also detected. Because it is well known that mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is strongly expressed in sinus-lining cells, anti-MAdCAM-1 antibodies were used for the detection of sinus-lining cells. As shown in mice were detected at comparable levels to those in TA3-Stbearing mice and control mice despite their slight reduction. These results are consistent with the results of flow cytometric analyses, and suggest that MZB cells are more affected by mucins than FOB cells, in spite of the similar level of Siglec-2 expression in both B cell subpopulations. It has been reported that MZB cells were reduced in Siglec-2-deficient mice or mice expressing mutant Siglec-2 molecules that lack ligandbinding activity (26, 27) , suggesting that interactions between Siglec-2 and endogenous ligands play an important role in the maintenance of MZB cells. These facts can be considered to indicate that mucins in the bloodstream physiologically prevent some interactions between Siglec-2 and endogenous ligands in the tumor-bearing state. To maintain MZB cells, what kind of interaction between Siglec-2 and endogenous ligands occurs and how they function are not known yet. These issues are interesting and under investigation. The reason why MZB cells are more affected by mucins than FOB cells, in spite of the similar levels of Siglec-2 expression in the two B cell subpopulations, is speculated to be as follows: It has been reported that a high proportion of MZB cells express unmasked Siglec-2, while Siglec-2 expressed on FOB cells is mostly masked by the cis ligand (28) . These facts suggest that Siglec-2 on MZB cells could be ligated with trans ligands more easily than that on FOB cells. Another possibility is the different microenvironmental conditions of the splenic marginal zone. The splenic artery divides into central arteries. Penicillary arteries branching from the central arteries feed into the marginal sinus. Cells in the marginal zone are constantly exposed to large amounts of blood and to bloodborne antigens, including mucins. In addition, a slow bloodflow rate in the marginal zone may facilitate the interaction between MZB cells and circulating epiglycanin.
D. Distribution of Mucins Taken into the Spleen from the Bloodstream
Next, we examined the distribution of epiglycanin taken into the spleen from the bloodstream. Alexa Fluor 488-labeled epiglycanin was injected intravenously into normal mice and, after 20 min, the mice were perfused with 4% paraformaldehyde through the heart, and then their spleens were resected. Frozen sections of these spleens were immunochemically stained by successive incubation with anti-MAdCAM-1 Ab, anti-CD1d Ab, or anti-Siglec-2 Ab and fluorescein-labeled secondary Ab. Epiglycanin was detected in the marginal zone. Furthermore, a considerable proportion of it was associated with CD1d-expressing MZB cells (24) , suggesting that epiglycanin is localized in the marginal zone through the interaction between epiglycanin and Siglec-2. When a similar experiment was performed using BSM, BSM was similarly detected in the marginal zone and associated with MZB cells. These results suggest that only epiglycanin was not specifically taken into the marginal zone. In other words, epiglycanin and BSM were incorporated into the marginal zone through their sialylated carbohydrate structures not through their core structures. In fact, Alexa Fluor 488-labeled asialo-BSM was not taken into the splenic marginal zone.
To further clarify the impairment of MZB cells by mucins, we examined the effect of repeated administration of BSM on MZB cells. One hundred μg of BSM was intravenously injected into normal mice every other day. As described above, the localization of the administered BSM in the spleen was similar to that of epiglycanin. Splenocytes were prepared from the mice on day 8. After successive incubation with anti-CD1d Ab or anti-CD21 Ab and fluorescein-labeled secondary Ab against each Ab, the cells were analyzed with a flow cytometer. On continuous administration of BSM, MZB cells clearly decreased to about 60% compared with in control mice, indicating that mucins are responsible for the impairment of MZB cells and that no other humoral factors produced by cancer cells are related to it.
E. Interaction between Mucins Taken from the Bloodstream and Splenic Cells Other than MZB Cells
It is generally known that blood-borne antigens are taken up by marginal zone macrophages (MZMs), marginal metallophilic macrophages (MMMs), and marginal zone dendritic cells (MDCs) in the spleen (29) . Mucins in the bloodstream may be also taken up by these cells. To determine whether or not these cells are also responsible for the trapping of mucins in the bloodstream, sections were prepared from mice into which labeled epiglycanin had been intravenously injected. Since MMMs and MZMs specifically express CD169 (Siglec-1) and SIGN-R1, a homologue of human DC-SIGN, respectively, these cells were detected with the respective Ab. MDCs were detected with anti-CD11c Ab. Actually, a portion of the labeled epiglycanin was also associated with MMMs, but hardly with MZMs and MDCs (24) . Since epiglycanin was associated with MMMs as well as MZB cells, mucins in the bloodstream may have some effect on MMMs. A receptor for epiglycanin on MMMs has not been found so far. CD169 expressed on MMMs is a member of the Siglec family, like Siglec-2, and Crocker et al. reported that CD169 binds to MUC1 (4) . Therefore, it is predicted that the association of epiglycanin with MMMs is mediated by CD169. Although the effects of mucins on MMMs have not been elucidated, CD169 may not be related to signal transduction, because CD169, unlike other members of the Siglec family, has no ITIM in its cytoplasmic region and considerd to be responsible for internalization of antigens leading to antigen presentation.
F. Immune Responses of Mice Bearing Mucin-Producing Carcinomas
Antigens can be classified into T cell-dependent ones (Thymus-dependent antigen; TD antigen) and T cellindependent ones (Thymus-independent antigen; TI antigen). TI antigens can be further subclassified into TI-1 and TI-2 ones. The former induces polyclonal activation of B cells such as LPS, but the latter does not. The capsular polysaccharides of Diplococcus pneumoniae and dextran, a large branched polysaccharide, are representative TI antigens, and have multiple epitopes. It is generally agreed that the TI-2 response is mainly exhibited by MZB cells and that upon activation by TI-2 antigens, MZB cells differentiate into plasma cells. The impairment of MZB cells in TA3-Ha-bearing mice let us to predict that the TI-2 response may be reduced in these mice. Thus, we next examined the TI-2 response in TA3-Ha-or TA3-St-bearing mice. A TI-2 antigen, TNP-Ficoll, was injected intravenously into TA3-Ha-or TA3-St-bearing mice on days 5 and 7 after inoculation of the tumor cells, and blood was taken on day 8. The production of anti-TNPIgM and -IgG was quantitated using TNP-BSA coated plates. Expectedly, the levels of anti-TNP-IgM and -IgG in TA3-Ha-bearing mice decreased to about 50% and 60% of that in control mice, respectively (24). In contrast, the level of anti-TNP Ab produced by TA3-St-bearing mice was similar to that by control mice. These results were highly consistent with the impairment of MZB cells in TA3-Ha-bearing mice.
It is generally agreed that the TD response is mainly exhibited by FOB cells. Therefore, the same levels of TD response could be expected among the above mice in contrast to the response to TI-2 antigens. The thymus-dependent (TD) response with a TD antigen, TNP-KLH, was examined. As expected, similar levels of anti-TNP-IgM and -IgG were produced in these tumor-bearing mice and control mice (24) , this being consistent with the finding that FOB cells are scarcely affected by mucins.
It is well known that splenic MZB cells rapidly respond to blood-borne pathogens and produce antibodies against them (30, 31) . A large number of these antibodies react with the capsular polysaccharides of the pathogens. Generally, the capsular polysaccharides of the pathogens are TI antigens. Since MZB cells play an important role in the uptake of bloodborne antigens and in subsequent anti-bacterial immunity, the impairment of MZB cells might increase the risk of sepsis caused by pathogens. In fact, it has been reported that splenectomy results in increased susceptibility to encapsulated bacteria such as Streptococcus pneumoniae or Diplococcus pneumoniae and an increased mortality rate caused by them (32) . It is known that the reduction of lymphocytes caused by chemotherapy and/or radiotherapy increases the risk of sepsis. If MZB cells are impaired by mucins in cancer patients like in a tumor-bearing mouse model, mucins in the bloodstream may increase the risk of sepsis in them. The correlation between mucins and the reduction of MZB cells in cancer patients is now under investigation.
G. Conclusions
Although mucins in the bloodstream have been clinically used as tumor-markers, their biological significance has not been focused on. Recently, some groups including ours reported biological studies from the standpoint of immunoregulation through interactions between mucins and lectins on immune cells (33) (34) (35) (36) (37) . Mucins produced by malignant epithelial cells are secreted into the tumor tissues and the bloodstream of cancer patients. Therefore, it is possible that mucins not only affect the cells that have invaded the tumor tissues but also the cells in the organ that passes through the bloodstream. We first demonstrated clearly that mucins carried by the bloodstream down-modulate B cell signal transduction and impair splenic MZB cells (Fig. 6) . In addition to B cells, our group is studying the biological effects of mucins on dendritic cells, NK cells, monocytes/ macrophages, and cancer cells themselves. These studies will facilitate understanding of the effects of mucins on these cells, on the host immune system, and consequently on the whole body.
